Patheon sells off its Mexican division for $34M

Contract drug developer Patheon has flipped its Mexican operations to Perrigo ($PRGO) for $34 million in cash, shifting its focus to the U.S. and Europe. Under the deal, Perrigo gets Patheon's softgel manufacturing and formulation capacity in Mexico. Patheon, part of the DPx conglomerate, has been investing elsewhere in North America, this week spending about $3 million to expand a North Carolina testing facility. Sale | Expansion

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.